glp-1 market news november 2025 ISPOR 2025: Exploring reasons for discontinuation GLP-1 Pharmacy Pricing Update (Dec

According to the SmPC, nausea is very common (affecting approximately 44% of patients), while vomiting, diarrhoea, constipation, and abdominal pain are common side effects

Treatment of Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease: Current Approaches and Future Directions

At first, another glucose-lowering option

Discussion of Table 1: Table 1 synthesizes available data on formulary access for Wegovy (a representative weight-loss GLP-1) under the top PBMs, plus a note on general employer plans

& Harris, A

Were going to deep-dive into the physiological differences that matter when selecting injection sites, how and when to rotate them, plus debunk some misinformation about the process